June 23, 2026—Diasorin has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration for its group A streptococcus assay, for use on the Liaison Nes point-of-care molecular diagnostics platform. The test provides actionable results as soon as a positive target is amplified, with definitive negative results in about 15 minutes, and features a hands-on time of less than one minute and room temperature reagents.
The FDA cleared the Liaison Nes Flu A/B, RSV and COVID-19 assay in December 2025.